Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 2Phase 1/2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 29Dermatologic 19Head & Neck 18Gastrointestinal 11Genitourinary 8Sarcoma 6Breast 5Tumor-Agnostic 4Other solid neoplasm 3Gynecologic 3Endocrine 3CNS 3Lymphoid 2Plasma cell 1

Conditions

Natural Killer/T-cell Lymphoma 1Hodgkin Disease 1

Interventions

Rituximab 689Cyclophosphamide 615Vincristine 285Etoposide 272Doxorubicin 271Cytarabine 230Prednisone 229Methotrexate 221fludarabine phosphate 189Filgrastim 187Dexamethasone 180fludarabine 176Lenalidomide 165Radiotherapy 128Melphalan 127Peripheral Blood Stem Cell Transplantation 123Busulfan 118Bendamustine Hydrochloride 116Granulocyte Colony-Stimulating Factor 113Bortezomib 112ibrutinib 111Mycophenolic Acid 110venetoclax 106Whole-Body Irradiation 106obinutuzumab 105Tacrolimus 105Gemcitabine 92zanubrutinib 81Specimen Handling 80Cyclosporine 76

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × cemiplimab × Lymphoid × Clear all
NCT04763616 2026-04-27

ICING

Samsung Medical Center

Phase 2 Completed
37 enrolled
Lymphoid

Natural Killer/T-cell Lymphoma

NCT04373083 2021-01-15

Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma

Regeneron Pharmaceuticals

Phase 2 Withdrawn
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡